Limits...
Icariin ameliorates neuropathological changes, TGF-β1 accumulation and behavioral deficits in a mouse model of cerebral amyloidosis.

Zhang ZY, Li C, Zug C, Schluesener HJ - PLoS ONE (2014)

Bottom Line: Icariin, a major constituent of flavonoids from the Chinese medicinal herb Epimedium brevicornum, exhibits multiple biological properties, including anti-inflammatory, neuroregulatory and neuroprotective activities.Therapeutic effects were monitored by behavioral tests, namely nesting assay, before and during the experimental treatment.Our results suggest that Icariin might be considered a promising therapeutic option for human AD.

View Article: PubMed Central - PubMed

Affiliation: Division of Immunopathology of the Nervous System, Institute of Pathology and Neuropathology, University of Tuebingen, Tuebingen, Germany.

ABSTRACT
Icariin, a major constituent of flavonoids from the Chinese medicinal herb Epimedium brevicornum, exhibits multiple biological properties, including anti-inflammatory, neuroregulatory and neuroprotective activities. Therefore, Icariin might be applied in treatment of neurodegenerative disorders, including Alzheimer's disease (AD), which is neuropathologically characterized by β-amyloid aggregation, hyperphosphorylated tau and neuroinflammation. Potential therapeutic effects of Icariin were investigated in an animal model of cerebral amyloidosis for AD, transgenic APP/PS1 mouse. Icariin was suspended in carboxymethylcellulose and given orally to APP/PS1 mice. Therapeutic effects were monitored by behavioral tests, namely nesting assay, before and during the experimental treatment. Following an oral treatment of 10 days, Icariin significantly attenuated Aβ deposition, microglial activation and TGF-β1 immunoreactivity at amyloid plaques in cortex and hippocampus of transgenic mice 5 months of age, and restored impaired nesting ability. Our results suggest that Icariin might be considered a promising therapeutic option for human AD.

Show MeSH

Related in: MedlinePlus

Icariin reduced β-amyloid (Aβ) deposition and microglial activation.Differences of Aβ plaque counts and Aβ+/Iba-1+/GFAP+ area percentages between treatment and control were analysed by unpaired t-test and results are represented in the bar graphs. A and B: In cortex and hippocampus of transgenic mouse brains from the Icariin group, numbers of amyloid plaques were significantly reduced. C and D: IR area percentages of Aβ staining were highly significantly reduced. E and F: Following Icariin treatment, Iba-1 IR was significantly reduced in cortex and hippocampus. G and H: GFAP IR was not significantly changed by Icariin treatment.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4125230&req=5

pone-0104616-g004: Icariin reduced β-amyloid (Aβ) deposition and microglial activation.Differences of Aβ plaque counts and Aβ+/Iba-1+/GFAP+ area percentages between treatment and control were analysed by unpaired t-test and results are represented in the bar graphs. A and B: In cortex and hippocampus of transgenic mouse brains from the Icariin group, numbers of amyloid plaques were significantly reduced. C and D: IR area percentages of Aβ staining were highly significantly reduced. E and F: Following Icariin treatment, Iba-1 IR was significantly reduced in cortex and hippocampus. G and H: GFAP IR was not significantly changed by Icariin treatment.

Mentions: The transgenic mice received Icariin suspension or vehicle by gavage for 10 days. The treatment with Icariin attenuated neuropathological change, compared to the age- and gender-matched control mice. The Icariin treatment reduced the plaque counts significantly in cortex (control = 155.4±13.2, Icariin = 95.0±12.6, p<0.05, n = 6) and hippocampus (control = 21.6±3.4, Icariin = 10.4±2.1, p<0.05; n = 6) (Figure 4A and B). Further analysis of the micro photos showed highly significantly decreased Aβ IR area in both cortex and hippocampus from the Icariin treatment group (cortex: control = 0.72±0.06%, Icariin = 0.51±0.10%, p<0.05; hippocampus: control = 0.63±0.12%, Icariin = 0.33±0.09%, p<0.05; n = 6) (Figure 4C and D). Notably, Aβ plaques had a smaller size and fewer branches (Figure 3A and B).


Icariin ameliorates neuropathological changes, TGF-β1 accumulation and behavioral deficits in a mouse model of cerebral amyloidosis.

Zhang ZY, Li C, Zug C, Schluesener HJ - PLoS ONE (2014)

Icariin reduced β-amyloid (Aβ) deposition and microglial activation.Differences of Aβ plaque counts and Aβ+/Iba-1+/GFAP+ area percentages between treatment and control were analysed by unpaired t-test and results are represented in the bar graphs. A and B: In cortex and hippocampus of transgenic mouse brains from the Icariin group, numbers of amyloid plaques were significantly reduced. C and D: IR area percentages of Aβ staining were highly significantly reduced. E and F: Following Icariin treatment, Iba-1 IR was significantly reduced in cortex and hippocampus. G and H: GFAP IR was not significantly changed by Icariin treatment.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4125230&req=5

pone-0104616-g004: Icariin reduced β-amyloid (Aβ) deposition and microglial activation.Differences of Aβ plaque counts and Aβ+/Iba-1+/GFAP+ area percentages between treatment and control were analysed by unpaired t-test and results are represented in the bar graphs. A and B: In cortex and hippocampus of transgenic mouse brains from the Icariin group, numbers of amyloid plaques were significantly reduced. C and D: IR area percentages of Aβ staining were highly significantly reduced. E and F: Following Icariin treatment, Iba-1 IR was significantly reduced in cortex and hippocampus. G and H: GFAP IR was not significantly changed by Icariin treatment.
Mentions: The transgenic mice received Icariin suspension or vehicle by gavage for 10 days. The treatment with Icariin attenuated neuropathological change, compared to the age- and gender-matched control mice. The Icariin treatment reduced the plaque counts significantly in cortex (control = 155.4±13.2, Icariin = 95.0±12.6, p<0.05, n = 6) and hippocampus (control = 21.6±3.4, Icariin = 10.4±2.1, p<0.05; n = 6) (Figure 4A and B). Further analysis of the micro photos showed highly significantly decreased Aβ IR area in both cortex and hippocampus from the Icariin treatment group (cortex: control = 0.72±0.06%, Icariin = 0.51±0.10%, p<0.05; hippocampus: control = 0.63±0.12%, Icariin = 0.33±0.09%, p<0.05; n = 6) (Figure 4C and D). Notably, Aβ plaques had a smaller size and fewer branches (Figure 3A and B).

Bottom Line: Icariin, a major constituent of flavonoids from the Chinese medicinal herb Epimedium brevicornum, exhibits multiple biological properties, including anti-inflammatory, neuroregulatory and neuroprotective activities.Therapeutic effects were monitored by behavioral tests, namely nesting assay, before and during the experimental treatment.Our results suggest that Icariin might be considered a promising therapeutic option for human AD.

View Article: PubMed Central - PubMed

Affiliation: Division of Immunopathology of the Nervous System, Institute of Pathology and Neuropathology, University of Tuebingen, Tuebingen, Germany.

ABSTRACT
Icariin, a major constituent of flavonoids from the Chinese medicinal herb Epimedium brevicornum, exhibits multiple biological properties, including anti-inflammatory, neuroregulatory and neuroprotective activities. Therefore, Icariin might be applied in treatment of neurodegenerative disorders, including Alzheimer's disease (AD), which is neuropathologically characterized by β-amyloid aggregation, hyperphosphorylated tau and neuroinflammation. Potential therapeutic effects of Icariin were investigated in an animal model of cerebral amyloidosis for AD, transgenic APP/PS1 mouse. Icariin was suspended in carboxymethylcellulose and given orally to APP/PS1 mice. Therapeutic effects were monitored by behavioral tests, namely nesting assay, before and during the experimental treatment. Following an oral treatment of 10 days, Icariin significantly attenuated Aβ deposition, microglial activation and TGF-β1 immunoreactivity at amyloid plaques in cortex and hippocampus of transgenic mice 5 months of age, and restored impaired nesting ability. Our results suggest that Icariin might be considered a promising therapeutic option for human AD.

Show MeSH
Related in: MedlinePlus